US 11857333

US Patent 11857333, titled "Integrated sleep diagnostic and therapeutic system and method," was granted to Cleveland Medical Devices Inc. The inventors listed are Hani Kayyali, Dan Bishop, and Brian M. Kolkowski. The application for this patent was filed on July 5, 2017, and the patent was issued on January 2, 2024.

Abstract:
The patent describes an integrated sleep diagnostic and therapeutic system and method. This system uses a diagnostic device to analyze a subject's sleep disorder or its symptoms and then either automatically or with human intervention, treats the subject physically or chemically to improve the condition. The diagnostic component can employ various sensors to measure respirations, cardiac signals, brain waves, blood gases, electromyography (EMG), electrooculography (EOG), and airway pressure. The treatment component may include devices for positive airway pressure (PAP), continuous positive airway pressure (CPAP), or chemical treatment (e.g., oxygen, carbon dioxide, or medication delivery). The system allows for remote monitoring and adjustment of treatment, as well as "training" the treatment device to correlate limited sensor data with a richer dataset from the diagnostic device for more accurate control.

Independent Claims Overview:

• Claim 1: This claim describes a sleep apnea treatment system that combines a data acquisition system with a CPAP device. The data acquisition system includes at least one sensor to measure a subject's physiological characteristics and an electronic component to receive and retransmit/transmit a signal from that sensor. The CPAP device has an electrical connection to receive this signal, and its operation (titration or adjustment) is based, at least in part, on the received signal.
• Claim 10: This claim details a treatment device for a sleep-related breathing disorder. It comprises a data acquisition system with at least one sensor for physiological characteristics and an electronic component to process and transmit the sensor's signal. A PAP device, which treats the breathing disorder, has an electrical connection to receive the transmitted signal and is adjusted based on it.
• Claim 11: This claim outlines a sleep apnea treatment system that features a data acquisition system (also described as a sleep screening device) with two or more sensors for physiological characteristics and an electronic component to wirelessly receive and retransmit/transmit signals. A CPAP device with a wireless receiver or transceiver receives these signals and is titrated or adjusted based on them.
• Claim 12: This claim describes a sleep apnea treatment system that includes a data acquisition system with at least one sensor providing an electrical signal of a physiological characteristic, an electronic component to process and transmit this signal, and a CPAP device with an electrical connection to receive the transmitted signal. The system also includes a remote monitoring station with a transceiver to receive the processed signal and transmit a command signal to the CPAP device, which then adjusts based on the command.
• Claim 13: This claim specifies a sleep apnea treatment system with a data acquisition system comprising at least three sensors that measure respiratory effort, pulse oximetry, and airflow. An electronic component receives and retransmits/transmits signals from these sensors. A CPAP device receives these signals and is titrated or adjusted based on them.
• Claim 14: Similar to Claim 13, this claim describes a sleep apnea treatment system with a data acquisition system having at least three sensors for respiratory effort, pulse oximetry, and airflow. An electronic component receives and retransmits/transmits these signals. The CPAP device receives the signals, has a display to visually represent them, and an interface for user input. The CPAP device is titrated or adjusted based on both the signals and user input.
• Claim 15: This claim describes a sleep-related breathing disorder treatment system with a data acquisition system having at least one physiological sensor and an electronic component for wirelessly receiving and retransmitting/transmitting its signal. A treatment interface device wirelessly receives, optionally processes, and retransmits/transmits this signal. A PAP device receives the signal from the treatment interface device and is titrated or adjusted based on it.
• Claim 16: This claim outlines a sleep-related breathing disorder treatment system featuring a data acquisition system with at least two sensors for at least one physiological characteristic and a video signal. An electronic component receives and retransmits/transmits these signals. A PAP device receives these signals and is titrated or adjusted based on them.
• Claim 17: This claim covers a method of treating a sleep-related breathing disorder. The steps include attaching at least one sensor to a subject and connecting it to a data acquisition system. Data is collected while the subject sleeps, and signals (either raw or processed) are retransmitted from the data acquisition system to a PAP or CPAP device. The PAP/CPAP device then periodically adjusts its flow of pressurized gas using at least part of the retransmitted or transmitted signal.
• Claim 20: This claim describes a sleeping disorder treatment system with a diagnostic device that includes a pulse oximeter sensor and generates a quantitative output of the severity of the disorder or symptoms. A treatment device physically or chemically treats the disorder or symptoms and can be adjusted using this quantitative output.

USPTO Database and CAFC 2026 Dockets Search:
A general search of the USPTO database confirms the existence and status of US Patent 11857333. The provided patent information is consistent with USPTO records.

Regarding the CAFC 2026 dockets, direct searches for "US11857333" within 2026 dockets did not yield specific case entries. However, the Google Patents page for US11857333B1 indicates "Family has litigation" and mentions a PTAB (Patent Trial and Appeal Board) case, IPR2025-00246, which is listed as "Pending - Instituted". This suggests ongoing challenges to the patent family, though not necessarily a direct CAFC docket filing in 2026 for this specific patent number based on the performed search.